S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups

Oramed Pharmaceuticals - ORMP Stock Forecast, Price & News

$6.48
-0.01 (-0.15%)
(As of 09/30/2022 09:01 PM ET)
Add
Compare
Today's Range
$6.40
$6.77
50-Day Range
$6.48
$9.91
52-Week Range
$3.59
$31.54
Volume
242,800 shs
Average Volume
898,193 shs
Market Capitalization
$251.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.75

Oramed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
390.0% Upside
$31.75 Price Target
Short Interest
Healthy
7.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.88mentions of Oramed Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.04) to ($1.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

811th out of 1,095 stocks

Pharmaceutical Preparations Industry

397th out of 547 stocks

ORMP stock logo

About Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

Oramed Oral Insulin Shows Evidence For NASH Treatment
Oramed Pharmaceuticals Inc. (ORMP)
Short Volatility Alert: Oramed Pharmaceuticals Inc.
Why Oramed Pharmaceuticals Stock Is On Fire Today
Dow Rises 75 Points; Kura Sushi USA Shares Spike Higher
Oramed Letter to Shareholders
Oramed Granted NASH Patent in Europe
See More Headlines
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Company Calendar

Last Earnings
1/10/2022
Today
10/02/2022
Next Earnings (Estimated)
11/23/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORMP
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.75
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+390.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-22,240,000.00
Net Margins
-542.64%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.70 million
Book Value
$4.46 per share

Miscellaneous

Free Float
36,148,000
Market Cap
$251.60 million
Optionable
Optionable
Beta
2.30

Key Executives

  • Mr. Nadav Kidron Esq.Mr. Nadav Kidron Esq. (Age 48)
    Pres, CEO & Exec. Chairman
    Comp: $1.23M
  • Mr. David Silberman CPA (Age 38)
    CFO & Treasurer
    Comp: $232.47k
  • Mr. Joshua Hexter (Age 52)
    Chief Operating & Bus. Officer
    Comp: $372.01k
  • Dr. Miriam Kidron Ph.D. (Age 82)
    Chief Scientific Officer & Director
    Comp: $694.12k
  • Mr. Michael Rabinowitz (Age 57)
    Chief Commercial Officer
    Comp: $430.94k
  • Mr. Netanel Derovan (Age 47)
    Chief Legal Officer & Company Sec.
  • Dr. Roy Eldor M.D.
    Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board













ORMP Stock - Frequently Asked Questions

Should I buy or sell Oramed Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ORMP shares.
View ORMP analyst ratings
or view top-rated stocks.

What is Oramed Pharmaceuticals' stock price forecast for 2022?

4 Wall Street analysts have issued 12-month price targets for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $20.00 to $40.00. On average, they predict the company's stock price to reach $31.75 in the next twelve months. This suggests a possible upside of 390.0% from the stock's current price.
View analysts price targets for ORMP
or view top-rated stocks among Wall Street analysts.

How have ORMP shares performed in 2022?

Oramed Pharmaceuticals' stock was trading at $14.28 at the beginning of 2022. Since then, ORMP stock has decreased by 54.6% and is now trading at $6.48.
View the best growth stocks for 2022 here
.

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 23rd 2022.
View our ORMP earnings forecast
.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.06. The biotechnology company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.70 million. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 9.72% and a negative net margin of 542.64%.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $6.48.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $251.60 million and generates $2.70 million in revenue each year. The biotechnology company earns $-22,240,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.

This page (NASDAQ:ORMP) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.